Disease · MONDO_0100342
Comparisons in its trials43
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 20 of 43
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Arm A: Ph 2 Radiation Therapy, TMZ and BMX-001 vs Arm B: Ph 2 Radiation Therapy and TMZ: Phase 2: Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability] | 17 of 80 | 13 of 80 | 160 | NCT02655601 | Trial comparisons |
| Arm A: Ph 2 Radiation Therapy, TMZ and BMX-001 vs Arm B: Ph 2 Radiation Therapy and TMZ: Phase 2: Protection of Bone Marrow Against Chemotherapy-Induced Thrombocytopenia | 1 of 78 | 2 of 71 | 149 | NCT02655601 | Trial comparisons |
| Phase 1 Dose Escalation vs Phase 2 Recurrent Malignant Gliomas and Nonprogressive Gbm: serious adverse events | 0 of 32 | 2 of 99 | 131 | NCT00045110 | Trial comparisons |
| Lerapolturev vs Lerapolturev + Lomustine: Number of Participants With Objective Radiographic Response | 5 of 93 | 2 of 27 | 120 | NCT02986178 | Trial comparisons |
| Lerapolturev vs Lerapolturev + Lomustine: Safety of Lerapolturev | 17 of 94 | 8 of 26 | 120 | NCT02986178 | Trial comparisons |
| Bevacizumab Resistant Patients vs Bevacizumab Naive Patients: Number of Participants With Adverse Events | 44 of 44 | 43 of 43 | 87 | NCT00923117 | Trial comparisons |
| Bevacizumab Resistant Patients vs Bevacizumab Naive Patients: serious adverse events | 16 of 44 | 13 of 43 | 87 | NCT00923117 | Trial comparisons |
| Metronomic Therapy Cohort vs Dose-Dense Therapy Cohort: deaths from any cause | 0 of 43 | 1 of 42 | 85 | NCT00200161 | Trial comparisons |
| Metronomic Therapy Cohort vs Dose-Dense Therapy Cohort: serious adverse events | 0 of 43 | 0 of 42 | 85 | NCT00200161 | Trial comparisons |
| Enzastaurin + Bevacizumab (NEIAED) vs Enzastaurin + Bevacizumab (EIAED): serious adverse events | 24 of 68 | 4 of 13 | 81 | NCT00586508 | Trial comparisons |
| Phase I (Erlotinib & Temsirolimus) vs Phase II (Erlotinib & Erlotinib): serious adverse events | 3 of 21 | 2 of 59 | 80 | NCT00112736 | Trial comparisons |
| Cohorts 1: Surgical Subjects vs Cohorts 2: Non-surgical Subjects: deaths from any cause | 0 of 15 | 2 of 50 | 65 | NCT01339052 | Trial comparisons |
| Cohorts 1: Surgical Subjects vs Cohorts 2: Non-surgical Subjects: serious adverse events | 5 of 15 | 12 of 50 | 65 | NCT01339052 | Trial comparisons |
| Glioblastoma vs Grade III Glioma: Patients With Tumors With Functional Alterations of the Mismatch Repair (MMR) System | 0 of 40 | 0 of 20 | 60 | NCT00619112 | Trial comparisons |
| Glioblastoma vs Grade III Glioma: Patients Progressing 6 Months After Temozolomide is Voluntarily Discontinued | 4 of 40 | 4 of 20 | 60 | NCT00619112 | Trial comparisons |
| Glioblastoma vs Grade III Glioma: Patients Progressing Within 6 Months After 6th Adjuvant Course of Temozolomide | 4 of 40 | 1 of 20 | 60 | NCT00619112 | Trial comparisons |
| Glioblastoma vs Grade III Glioma: Patients Progressing After Two First-line Adjuvant Courses of Temozolomide | 3 of 40 | 0 of 20 | 60 | NCT00619112 | Trial comparisons |
| Grade III vs Grade IV: Safety of Study Treatment Regimen | 9 of 32 | 13 of 27 | 59 | NCT00612430 | Trial comparisons |
| Grade III vs Grade IV: serious adverse events | 2 of 32 | 3 of 27 | 59 | NCT00612430 | Trial comparisons |
| EIAED vs Non-EIAED: Number of Patients With Grade 3 or Greater, Treatment-related, Non-hematologic Toxicities | 27 of 28 | 24 of 28 | 56 | NCT00611325 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0100342/comparisons